Myocardial Infarction With ST Segment Elevation Myocardial Infarction With ST Segment Elevation Overview

Myocardial infarction with
ST-segment elevation
overview
A NICE !a%h(a* b#ing$ %ge%he# all NICE g&idance, "&ali%*
$%anda#d$ and ma%e#ial$ % $&!!#% im!lemen%a%in n a $!eci,c
%!ic a#ea. The !a%h(a*$ a#e in%e#ac%i'e and de$igned % be &$ed
nline. Thi$ !df 'e#$in gi'e$ *& a $ingle !a%h(a* diag#am and
&$e$ n&mbe#ing % link %he b)e$ in %he diag#am % %he a$$cia%ed
#ecmmenda%in$.
T 'ie( %he nline 'e#$in f %hi$ !a%h(a* 'i$i%:
h%%!://!a%h(a*$.nice.#g.&k/!a%h(a*$/m*ca#dial-infa#c%in-(i%h-
$%-$egmen%-ele'a%in
Pa%h(a* la$% &!da%ed: 04 Se!%embe# 2014
C!*#igh% + NICE 2014. All #igh%$ #e$e#'ed
NICEPathways Pathways
Myocardial infarction with ST-segment elevation overview NICE Pathways
Myocardial infarction with ST-segment elevation pathway
Copyright NICE 2014. Pathway last updated: 04 September 2014
Page 2 of 12
1 Person with acute myocardial infarction with ST-segment elevation
No additional information
2 Immediately assess eligibility for coronary reperfusion therapy
Immediately assess eligibility (irrespective of age, ethnicity or sex) for coronary reperfusion
therapy (either primary PCI or fibrinolysis) in people with acute STEMI.
Do not use level of consciousness after cardiac arrest caused by suspected acute STEMI to
determine whether a person is eligible for coronary angiography (with follow-on primary PCI if
indicated).
Resources
The following implementation tools are relevant to this part of the pathway.
Myocardial infarction with ST-segment-elevation: clinical audit tool
Myocardial infarction with ST-segment-elevation: costing report
Myocardial infarction with ST-segment-elevation: costing template
3 If eligible, deliver coronary reperfusion therapy as quickly as possible
4 When to offer coronary angiography, with follow-on coronary
revascularisation if indicated
Offer coronary angiography, with follow-on primary PCI if indicated, as the preferred coronary
reperfusion strategy for people with acute STEMI if:
presentation is within 12 hours of onset of symptoms and
primary PCI can be delivered within 120 minutes of the time when fibrinolysis could have
been given.
Page 3 of 12
Offer coronary angiography, with follow-on primary PCI if indicated, to people with acute STEMI
and cardiogenic shock who present within 12 hours of the onset of symptoms of STEMI.
Consider coronary angiography, with follow-on primary PCI if indicated, for people with acute
STEMI presenting more than 12 hours after the onset of symptoms if there is evidence of
continuing myocardial ischaemia.
Consider coronary angiography, with a view to coronary revascularisation if indicated, for people
with acute STEMI who present more than 12 hours after the onset of symptoms and who have
cardiogenic shock or go on to develop it.
Quality standards
The following quality statement is relevant to this part of the pathway.
5. Level of consciousness and eligibility for coronary angiography and primary PCI
5 Treatment with primary percutaneous coronary intervention
Consider thrombus aspiration during primary PCI for people with acute STEMI.
Do not routinely use mechanical thrombus extraction during primary PCI for people with acute
STEMI.
Consider radial (in preference to femoral) arterial access for people undergoing coronary
angiography (with follow-on primary PCI if indicated).
Do not offer routine glycoprotein IIb/IIIa inhibitors or fibrinolytic drugs before arrival at the
catheter laboratory to people with acute STEMI for whom primary PCI is planned.
Antiplatelet agents
Ticagrelor
Ticagrelor in combination with low-dose aspirin is recommended for up to 12 months as a
treatment option in people with STEMI defined as ST elevation or new left bundle branch
block on electrocardiogram that cardiologists intend to treat with primary PCI.
Page 4 of 12
This recommendation is adapted from Ticagrelor for the treatment of acute coronary syndromes
(NICE technology appraisal guidance 236).
NICE has written information for the public explaining the guidance on ticagrelor.
Prasugrel
Prasugrel 10 mg in combination with aspirin is recommended as an option within its marketing
authorisation, that is, for preventing atherothrombotic events in adults with acute coronary
syndrome (unstable angina, non-ST-segment elevation myocardial infarction or STEMI) having
primary or delayed PCI.
This recommendation is from Prasugrel with percutaneous coronary intervention for treating
acute coronary syndromes (review of technology appraisal guidance 182) (NICE technology
appraisal guidance 317).
NICE has written information for the public explaining the guidance on prasugrel.
Anti-thrombin agents
Heparin
Offer unfractionated heparin or low molecular weight heparin to people with acute STEMI who
are undergoing primary PCI and have been treated with prasugrel or ticagrelor.
Bivalirudin
Bivalirudin in combination with aspirin and clopidogrel is recommended for the treatment of
adults with STEMI undergoing primary PCI.
This recommendation is from Bivalirudin for the treatment of ST-segment-elevation myocardial
infarction (NICE technology appraisal guidance 230).
NICE has written information for the public explaining the guidance on bivalirudin.
Stents
Drug-eluting stents
Drug-eluting stents are recommended for use in PCI for the treatment of coronary artery
disease, within their instructions for use, only if:
Page 5 of 12
the target artery to be treated has less than a 3-mm calibre or the lesion is longer than 15
mm, and
the price difference between drug-eluting stents and bare-metal stents is no more than
300.
This recommendation is from Drug-eluting stents for the treatment of coronary artery disease
(NICE technology appraisal guidance 152).
NICE has written information for the public explaining the guidance on drug-eluting stents.
Coronary artery stents
Stents should be used routinely where PCI is the clinically appropriate procedure for patients
with either stable or unstable angina or with acute myocardial infarction.
This guidance specifically relates to the present clinical indications for PCI and excludes
conditions (such as many cases of stable angina) that are adequately managed with standard
drug therapy.
These recommendations are from Guidance on the use of coronary artery stents (NICE
technology appraisal guidance 71).
NICE has written information for the public explaining the guidance on coronary artery stents.
Bioresorbable stents
NICE has published guidance on bioresorbable stent implantation for treating coronary artery
disease (NICE interventional procedure guidance 492) with special arrangements for clinical
governance, consent and audit or research.
Optical coherence tomography
NICE has published guidance on optical coherence tomography to guide percutaneous
coronary intervention (NICE interventional procedure guidance 481) with special
arrangements for consent, audit and clinical governance.
Resources
Page 6 of 12
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes:
costing statement
Ticagrelor for the treatment of acute coronary syndromes: clinical audit tool
Ticagrelor for the treatment of acute coronary syndromes: costing template
Bivalirudin for the treatment of ST-segment-elevation myocardial infarction: clinical audit tool
Bivalirudin for the treatment of ST-segment-elevation myocardial infarction: costing template
Drug-eluting stents for the treatment of coronary artery disease: costing template
Drug-eluting stents for the treatment of coronary artery disease: audit support
6 When to offer fibrinolysis
Offer fibrinolysis to people with acute STEMI presenting within 12 hours of onset of symptoms if
primary PCI cannot be delivered within 120 minutes of the time when fibrinolysis could have
been given.
7 Treatment with fibrinolysis
When treating people with fibrinolysis, give an antithrombin at the same time.
Thrombolytic drugs
This guidance provides recommendations on the selection of thrombolytic drugs in patients with
acute myocardial infarction. Recommendations are made in relation to the use of the drugs in
hospital and pre-hospital settings. The guidance does not compare hospital and pre-hospital
models of delivering thrombolysis.
It is recommended that, in hospital, the choice of thrombolytic drug (alteplase, reteplase,
streptokinase or tenecteplase) should take account of:
the likely balance of benefit and harm (for example, stroke) to which each of the
thrombolytic agents would expose the individual patient
current UK clinical practice, in which it is accepted that patients who have
previously received streptokinase should not be treated with it again
Page 7 of 12
the hospital's arrangements for reducing delays in the administration of
thrombolysis.
Where pre-hospital delivery of thrombolytic drugs is considered a beneficial approach as
part of an emergency-care pathway for acute myocardial infarction (for example, because
of population geography or the accessibility of acute hospital facilities), the practicalities of
administering thrombolytic drugs in pre-hospital settings mean that the bolus drugs
(reteplase or tenecteplase) are recommended as the preferred option.
These recommendations are from Guidance on the use of drugs for early thrombolysis in the
treatment of acute myocardial infarction (NICE technology appraisal guidance 52).
NICE has written information for the public explaining its guidance on thrombolytic drugs.
8 What to do after treatment with fibrinolysis
Offer an electrocardiogram to people treated with fibrinolysis, 6090 minutes after
administration. For those who have residual ST-segment elevation suggesting failed coronary
reperfusion:
offer immediate coronary angiography, with follow-on PCI if indicated
do not repeat fibrinolytic therapy.
If a person has recurrent myocardial ischaemia after fibrinolysis, seek immediate specialist
cardiological advice and, if appropriate, offer coronary angiography, with follow-on PCI if
indicated.
Consider coronary angiography during the same hospital admission for people who are clinically
stable after successful fibrinolysis.
Stents
NICE has written guidance on drug-eluting stents for the treatment of coronary artery disease,
and guidance on the use of coronary artery stents. See treatment with primary percutaneous
coronary intervention in this pathway for more information.
9 If ineligible, offer medical therapy
Page 8 of 12
10 Offer information, advice, support and treatment on related conditions
and secondary prevention
Offer people who have had an acute STEMI written and oral information, advice, support and
treatment on related conditions and secondary prevention (including lifestyle advice), as
relevant, in line with published NICE guidance (see below).
Lifestyle issues
Smoking cessation: see the smoking cessation pathway
Diet, weight management and exercise: see the diet pathway and physical activity pathway
Related conditions
Lipid modification and statin therapy:
Familial hypercholesterolaemia: see the familial hypercholesterolaemia pathway
(Lipid modification: see the cardiovascular disease prevention pathway
(Statins for the prevention of cardiovascular events: see the cardiovascular disease
prevention pathway
Prevention, diagnosis and management of diabetes: see the diabetes pathway
Prevention, diagnosis and management of high blood pressure: see the hypertension
pathway
Hyperglycaemia management in acute coronary syndromes: see the hyperglycaemia in
acute coronary syndromes pathway
MI secondary prevention: secondary prevention in primary and secondary care for
patients following a myocardial infarction: see the myocardial infarction: secondary
prevention pathway
General guidance
patient experience: see the patient experience in adult NHS services pathway
Medicines adherence: see the medicines adherence pathway
Information for the public
NICE has written information for the public explaining the guidance on:
familial hypercholersterolaemia
Lipid modification: cardiovascular risk assessment and the modification of blood lipids for
the primary and secondary prevention of cardiovascular disease
Page 9 of 12
type 2 diabetes
type 1 diabetes
hypertension
hyperglycaemia in acute coronary syndromes
myocardial infarction secondary prevention
patient experience in adult NHS services and
medicines adherence.
11 Commissioning primary percutaneous coronary intervention services
When commissioning primary PCI services for people with acute STEMI, be aware that
outcomes are strongly related to how quickly primary PCI is delivered, and that they can be
influenced by the number of procedures carried out by the primary PCI centre.
Resources
Myocardial infarction with ST-segment-elevation: costing report
Myocardial infarction with ST-segment-elevation: costing template
12 NICE pathway on myocardial infarction: secondary prevention
See Myocardial infarction: secondary prevention
13 NICE pathway on patient experience in adult NHS services
See Patient experience in adult NHS services / Patient experience in adult NHS services
overview
Page 10 of 12
Glossary
Sources
Myocardial infarction with ST-segment-elevation. NICE clinical guideline 167 (2013)
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes
(review of technology appraisal guidance 182). NICE technology appraisal guidance 317 (2014)
Ticagrelor for the treatment of acute coronary syndromes. NICE technology appraisal guidance
236 (2011)
Bivalirudin for the treatment of ST-segment-elevation myocardial infarction. NICE technology
appraisal guidance 230 (2011)
Drug-eluting stents for the treatment of coronary artery disease. NICE technology appraisal
guidance 152 (2008)
Guidance on the use of coronary artery stents. NICE technology appraisal guidance 71 (2003)
Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial
infarction. NICE technology appraisal guidance 52 (2002)
Bioresorbable stent implantation for treating coronary artery disease. NICE interventional
procedure guidance 492 (2014)
Optical coherence tomography to guide percutaneous coronary intervention. NICE
interventional procedure guidance 481 (2014)
Your responsibility
The guidance in this pathway represents the view of NICE, which was arrived at after careful
consideration of the evidence available. Those working in the NHS, local authorities, the wider
public, voluntary and community sectors and the private sector should take it into account when
carrying out their professional, managerial or voluntary duties. Implementation of this guidance
is the responsibility of local commissioners and/or providers. Commissioners and providers are
reminded that it is their responsibility to implement the guidance, in their local context, in light of
their duties to avoid unlawful discrimination and to have regard to promoting equality of
Page 11 of 12
opportunity. Nothing in this guidance should be interpreted in a way which would be inconsistent
with compliance with those duties.
Copyright
Copyright National Institute for Health and Care Excellence 2014. All rights reserved. NICE
copyright material can be downloaded for private research and study, and may be reproduced
for educational and not-for-profit purposes. No reproduction by or for commercial organisations,
or for commercial purposes, is allowed without the written permission of NICE.
Contact NICE
National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT
www.nice.org.uk
nice@nice.org.uk
0845 003 7781
Page 12 of 12

Myocardial Infarction With ST Segment Elevation Myocardial Infarction With ST Segment Elevation Overview

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Myocardial Infarction With ST Segment Elevation Myocardial Infarction With ST Segment Elevation Overview

Uploaded by

Copyright:

Available Formats

Myocardial infarction with

You might also like